share_log

Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target

Benzinga ·  Aug 4, 2023 08:41

Jefferies analyst Maury Raycroft upgrades BioCryst Pharma (NASDAQ:BCRX) from Hold to Buy and announces $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment